ENTRY       hsa05220                    Pathway
NAME        Chronic myeloid leukemia - Homo sapiens (human)
DESCRIPTION Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22. The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.
CLASS       Human Diseases; Cancer: specific types
PATHWAY_MAP hsa05220  Chronic myeloid leukemia
NETWORK     nt06210  ERK signaling (cancer)
            nt06214  PI3K signaling (cancer)
            nt06218  TGFB signaling (cancer)
            nt06219  JAK-STAT signaling (cancer)
            nt06230  Cell cycle (cancer)
            nt06240  Transcription (cancer)
            nt06260  Colorectal cancer
            nt06261  Gastric cancer
            nt06262  Pancreatic cancer
            nt06263  Hepatocellular carcinoma
            nt06265  Bladder cancer
            nt06266  Non-small cell lung cancer
            nt06267  Small cell lung cancer
            nt06268  Melanoma
            nt06269  Basal cell carcinoma
            nt06270  Breast cancer
            nt06271  Endometrial cancer
            nt06273  Glioma
            nt06274  Thyroid cancer
            nt06276  Chronic myeloid leukemia
  ELEMENT   N00002  BCR-ABL fusion kinase to RAS-ERK signaling pathway
            N00048  BCR-ABL fusion kinase to PI3K signaling pathway
            N00055  BCR-ABL fusion kinase to Jak-STAT signaling pathway
            N00067  Deleted p14(ARF) to p21-cell cycle G1/S
            N00070  Mutation-inactivated p16(INK4a) to p16-cell cycle G1/S
            N00074  Loss of RB1 to cell cycle G1/S
            N00106  AML1-EVI1 fusion to TGF-beta signaling pathway
            N00107  EVI-1 overexpression to TGF-beta signaling pathway
            N00115  Mutation-inactivated TP53 to transcription
DISEASE     H00004  Chronic myeloid leukemia
DRUG        D01441  Imatinib mesylate (USAN)
            D03252  Bosutinib (USAN)
            D03658  Dasatinib (JAN/INN)
            D06320  Vorinostat (JAN/USAN)
            D06413  Nilotinib hydrochloride hydrate (JAN)
            D06414  Dasatinib (USAN)
            D08066  Imatinib (INN)
            D08953  Nilotinib (USAN/INN)
            D08956  Omacetaxine mepesuccinate (USAN)
            D09728  Bosutinib hydrate (JAN)
            D09950  Ponatinib (USAN/INN)
            D09951  Ponatinib hydrochloride (JAN/USAN)
            D10176  Trametinib dimethyl sulfoxide (JAN/USAN)
            D10202  Bafetinib (USAN)
            D11404  Asciminib hydrochloride (JAN/USAN)
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        10000  AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1]
            1019  CDK4; cyclin dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
            1021  CDK6; cyclin dependent kinase 6 [KO:K02091] [EC:2.7.11.22]
            1026  CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625]
            1027  CDKN1B; cyclin dependent kinase inhibitor 1B [KO:K06624]
            1029  CDKN2A; cyclin dependent kinase inhibitor 2A [KO:K06621]
            10912  GADD45G; growth arrest and DNA damage inducible gamma [KO:K04402]
            110117499  P3R3URF-PIK3R3; P3R3URF-PIK3R3 readthrough [KO:K02649]
            1147  CHUK; component of inhibitor of nuclear factor kappa B kinase complex [KO:K04467] [EC:2.7.11.10]
            1398  CRK; CRK proto-oncogene, adaptor protein [KO:K04438]
            1399  CRKL; CRK like proto-oncogene, adaptor protein [KO:K04438]
            1487  CTBP1; C-terminal binding protein 1 [KO:K04496] [EC:1.1.1.428]
            1488  CTBP2; C-terminal binding protein 2 [KO:K04496] [EC:1.1.1.428]
            1643  DDB2; damage specific DNA binding protein 2 [KO:K10140]
            1647  GADD45A; growth arrest and DNA damage inducible alpha [KO:K04402]
            1869  E2F1; E2F transcription factor 1 [KO:K17454]
            1870  E2F2; E2F transcription factor 2 [KO:K09389]
            1871  E2F3; E2F transcription factor 3 [KO:K06620]
            207  AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1]
            208  AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1]
            2122  MECOM; MDS1 and EVI1 complex locus [KO:K04462] [EC:2.1.1.367]
            25  ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase [KO:K06619] [EC:2.7.10.2]
            25759  SHC2; SHC adaptor protein 2 [KO:K17447]
            2885  GRB2; growth factor receptor bound protein 2 [KO:K04364]
            3065  HDAC1; histone deacetylase 1 [KO:K06067] [EC:3.5.1.98]
            3066  HDAC2; histone deacetylase 2 [KO:K06067] [EC:3.5.1.98]
            3265  HRAS; HRas proto-oncogene, GTPase [KO:K02833]
            3551  IKBKB; inhibitor of nuclear factor kappa B kinase subunit beta [KO:K07209] [EC:2.7.11.10]
            369  ARAF; A-Raf proto-oncogene, serine/threonine kinase [KO:K08845] [EC:2.7.11.1]
            3845  KRAS; KRAS proto-oncogene, GTPase [KO:K07827]
            399694  SHC4; SHC adaptor protein 4 [KO:K17449]
            4088  SMAD3; SMAD family member 3 [KO:K23605]
            4089  SMAD4; SMAD family member 4 [KO:K04501]
            4193  MDM2; MDM2 proto-oncogene [KO:K06643] [EC:2.3.2.27]
            4609  MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377]
            4616  GADD45B; growth arrest and DNA damage inducible beta [KO:K04402]
            4790  NFKB1; nuclear factor kappa B subunit 1 [KO:K02580]
            4792  NFKBIA; NFKB inhibitor alpha [KO:K04734]
            4893  NRAS; NRAS proto-oncogene, GTPase [KO:K07828]
            51426  POLK; DNA polymerase kappa [KO:K03511] [EC:2.7.7.7]
            5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
            5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
            5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
            5295  PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649]
            5296  PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649]
            53358  SHC3; SHC adaptor protein 3 [KO:K17448]
            5594  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            5595  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            5604  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
            5605  MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
            572  BAD; BCL2 associated agonist of cell death [KO:K02158]
            578  BAK1; BCL2 antagonist/killer 1 [KO:K14021]
            5781  PTPN11; protein tyrosine phosphatase non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
            581  BAX; BCL2 associated X, apoptosis regulator [KO:K02159]
            5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
            5925  RB1; RB transcriptional corepressor 1 [KO:K06618]
            595  CCND1; cyclin D1 [KO:K04503]
            5970  RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735]
            598  BCL2L1; BCL2 like 1 [KO:K04570]
            613  BCR; BCR activator of RhoGEF and GTPase [KO:K08878] [EC:2.7.11.1]
            6464  SHC1; SHC adaptor protein 1 [KO:K06279]
            6654  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099]
            6655  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099]
            673  BRAF; B-Raf proto-oncogene, serine/threonine kinase [KO:K04365] [EC:2.7.11.1]
            6776  STAT5A; signal transducer and activator of transcription 5A [KO:K11223]
            6777  STAT5B; signal transducer and activator of transcription 5B [KO:K11224]
            7040  TGFB1; transforming growth factor beta 1 [KO:K13375]
            7042  TGFB2; transforming growth factor beta 2 [KO:K13376]
            7043  TGFB3; transforming growth factor beta 3 [KO:K13377]
            7046  TGFBR1; transforming growth factor beta receptor 1 [KO:K04674] [EC:2.7.11.30]
            7048  TGFBR2; transforming growth factor beta receptor 2 [KO:K04388] [EC:2.7.11.30]
            7157  TP53; tumor protein p53 [KO:K04451]
            8503  PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649]
            8517  IKBKG; inhibitor of nuclear factor kappa B kinase regulatory subunit gamma [KO:K07210]
            861  RUNX1; RUNX family transcription factor 1 [KO:K08367]
            867  CBL; Cbl proto-oncogene [KO:K04707] [EC:2.3.2.27]
            9846  GAB2; GRB2 associated binding protein 2 [KO:K08091]
COMPOUND    C05981  Phosphatidylinositol-3,4,5-trisphosphate
REFERENCE   PMID:15719031
  AUTHORS   Ren R.
  TITLE     Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
  JOURNAL   Nat Rev Cancer 5:172-83 (2005)
            DOI:10.1038/nrc1567
REFERENCE   PMID:11071626
  AUTHORS   Deininger MW, Goldman JM, Melo JV.
  TITLE     The molecular biology of chronic myeloid leukemia.
  JOURNAL   Blood 96:3343-56 (2000)
REFERENCE   PMID:14982876
  AUTHORS   Calabretta B, Perrotti D.
  TITLE     The biology of CML blast crisis.
  JOURNAL   Blood 103:4010-22 (2004)
            DOI:10.1182/blood-2003-12-4111
REFERENCE   PMID:10403855
  AUTHORS   Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM.
  TITLE     The biology of chronic myeloid leukemia.
  JOURNAL   N Engl J Med 341:164-72 (1999)
            DOI:10.1056/NEJM199907153410306
REFERENCE   PMID:15156182
  AUTHORS   Mitani K.
  TITLE     Molecular mechanisms of leukemogenesis by AML1/EVI-1.
  JOURNAL   Oncogene 23:4263-9 (2004)
            DOI:10.1038/sj.onc.1207777
REFERENCE   PMID:16484590
  AUTHORS   Dong M, Blobe GC.
  TITLE     Role of transforming growth factor-beta in hematologic malignancies.
  JOURNAL   Blood 107:4589-96 (2006)
            DOI:10.1182/blood-2005-10-4169
REFERENCE   PMID:9834202
  AUTHORS   Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H.
  TITLE     The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
  JOURNAL   Blood 92:4003-12 (1998)
REFERENCE   PMID:12801837
  AUTHORS   Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA.
  TITLE     p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
  JOURNAL   Haematologica 88:622-30 (2003)
REFERENCE   PMID:11160144
  AUTHORS   Baldwin AS.
  TITLE     Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.
  JOURNAL   J Clin Invest 107:241-6 (2001)
            DOI:10.1172/JCI11991
REFERENCE   PMID:12244301
  AUTHORS   Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL.
  TITLE     PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
  JOURNAL   Nat Med 8:1145-52 (2002)
            DOI:10.1038/nm759
REFERENCE   PMID:22286129
  AUTHORS   Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V
  TITLE     BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
  JOURNAL   Nat Chem Biol 8:285-93 (2012)
            DOI:10.1038/nchembio.775
REL_PATHWAY hsa04010  MAPK signaling pathway
            hsa04110  Cell cycle
            hsa04115  p53 signaling pathway
            hsa04151  PI3K-Akt signaling pathway
            hsa04210  Apoptosis
            hsa04350  TGF-beta signaling pathway
            hsa04640  Hematopoietic cell lineage
KO_PATHWAY  ko05220
///
